

CEO Subscribes for Units in Modus' Ongoing Rights Issue

Modus Therapeutics Holding AB's CEO, John Öhd, has informed the Company of his intention to, through the exercise of unit rights, subscribe for units amounting to at least SEK 500,000 in the ongoing rights issue. The rights issue was resolved by the Company's Board of Directors on 26 June 2025 and subsequently approved by the General Meeting on 29 July 2025. The subscription has been made possible through the sale of unused unit rights. The subscription period runs until 26 August 2025, and trading in unit rights continues until 21 August 2025.

For more information on Modus Therapeutics, please contact:

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: john.ohd@modustx.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Website: www.skmg.se

About Modus Therapeutics and sevuparin

Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus' ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Attachments

CEO Subscribes for Units in Modus' Ongoing Rights Issue